gengraf.com Report : Visit Site

Technical data of the gengraf.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host gengraf.com. Currently, hosted in United Kingdom and its service provider is Rackspace Ltd. .

the related websites

nbdominica.com physicalgeography.net hse.gov.uk yougov.co.uk industrialmachines.net core.telegram.org typeonline.co.uk 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Microsoft-IIS/8.5 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

menu home resources important safety information full prescribing information contact medical information affordable. flexible. dependable. write daw. fight kidney, liver, and heart transplant rejection with gengraf ® affordable immunosuppression for your kidney, liver, and heart transplant patients co-pays are less than branded and generic modified cyclosporines¹ 85% of gengraf patients' co-pay costs are less than $20¹ *indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. -- capsules not actual size flexible dosing options available in: 25-mg capsules 100-mg capsules 100-mg oral solution depend on daw to ensure your patients receive gengraf that you prescribe 2 100% of your patients receive gengraf when you write daw² as you may know, additional blood testing is required when switching to other modified cyclosporines³ important safety information 4 only physicians experienced in the management of systemic immunosuppressive therapy for the indicated disease should prescribe gengraf. at doses used in solid organ transplantation, only physicians experienced in immunosuppressive therapy and management of organ transplant recipients should prescribe gengraf. patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. the physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient. gengraf, a systemic immunosuppressant, may increase susceptibility to infection and the development of neoplasia. in kidney, liver, and heart transplant patients, gengraf may be administered with other immunosuppressive agents. increased susceptibility to infection and the possible development of lymphoma and other neoplasms may result from the increase in the degree of immunosuppression in transplant patients. gengraf capsules (cyclosporine capsules, usp [modified]) has increased bioavailability in comparison to sandimmune ® * soft gelatin capsules (cyclosporine capsules, usp). gengraf and sandimmune are not bioequivalent and cannot be used interchangeably without physician supervision. for a given trough concentration, cyclosporine exposure will be greater with gengraf than with sandimmune. if a patient who is receiving exceptionally high doses of sandimmune is converted to gengraf, particular caution should be exercised. cyclosporine blood concentrations should be monitored in transplant patients taking gengraf to avoid toxicity due to high concentrations. dose adjustments should be made in transplant patients to minimize possible organ rejection due to low concentrations. comparison of blood concentrations in the published literature with blood concentrations obtained using current assays must be done with detailed knowledge of the assay methods employed. cyclosporine, the active ingredient in gengraf, in recommended dosages, can cause systemic hypertension and nephrotoxicity. the risk increases with increasing dose and duration of cyclosporine therapy. renal dysfunction, including structural kidney damage, is a potential consequence of cyclosporine; therefore, renal function must be monitored during therapy. contraindications gengraf is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. warnings gengraf can cause nephrotoxicity and hepatotoxicity. the risk increases with increasing doses of gengraf; therefore, renal and hepatic function must be monitored during therapy. due to the potential for additive or synergistic impairment of renal function, caution should be taken when using gengraf with other nephrotoxic drugs or other drugs that impair renal function. patients receiving gengraf require frequent monitoring of serum creatinine. elderly patients should be monitored with particular care, since decreases in renal function occur with age. nephrotoxicity: gengraf can cause nephrotoxicity and hepatotoxicity when used in high doses. it is not unusual for serum creatinine and bun levels to be elevated during cyclosporine therapy. these elevations in renal transplant patients do not necessarily indicate rejection, and each patient must be fully evaluated before dosage adjustment is initiated. thrombotic microangiopathy: occasionally patients have developed a syndrome of thrombocytopenia and microangiopathic hemolytic anemia, which may result in graft failure. hyperkalemia: significant hyperkalemia (sometimes associated with hyperchloremic metabolic acidosis) and hyperuricemia have been seen occasionally in individual patients. hepatotoxicity: cases of hepatotoxicity and liver injury, including cholestasis, jaundice, hepatitis, and liver failure, have been reported in patients treated with cyclosporine. in some cases, mainly in transplant patients, fatal outcomes have been reported. malignancies: patients receiving cyclosporine are at increased risk for the development of lymphomas and other malignancies, particularly those of the skin. patients taking cyclosporine should be warned to avoid excess exposure to ultraviolet light. some malignancies may be fatal. serious infections: patients receiving gengraf are at increased risk of developing bacterial, viral, fungal, and protozoal infections, including opportunistic infections. these infections may lead to serious, including fatal, outcomes. polyoma virus infections: patients receiving gengraf are at increased risk for opportunistic infections, including polyoma virus infections. polyoma virus infections in transplant patients may have serious and sometimes fatal outcomes. these include cases of jc virus–associated progressive multifocal leukoencephalopathy (pml) and polyoma virus–associated nephropathy (pvan), especially due to bk virus infection. neurotoxicity: there have been reports of convulsions in adult and pediatric patients receiving cyclosporine, particularly in combination with high-dose methylprednisolone. encephalopathy, including posterior reversible encephalopathy syndrome (pres), has been described both in postmarketing reports and in the literature. special excipients – alcohol (ethanol): the alcohol content of gengraf should be taken into account when given to patients in whom alcohol intake should be avoided or minimized, e.g., pregnant or breastfeeding women, patients presenting with liver disease or epilepsy, alcoholic patients, or pediatric patients. precautions hypertension: hypertension is a common side effect of cyclosporine therapy that may persist; antihypertensive therapy may be required. however, since cyclosporine may cause hyperkalemia, potassium-sparing diuretics should not be used. vaccination: during treatment with cyclosporine, vaccination may be less effective; the use of live attenuated vaccines should be avoided. drug interactions: a number of drugs are well substantiated to interact with cyclosporine. in addition, concomitant use of nsaids with cyclosporine, particularly in the setting of dehydration, may potentiate renal dysfunction. caution should be exercised when using other drugs which are known to impair renal function, and close monitoring of renal function (in particular serum creatinine) should be performed. cyp3a inhibitors may result in increased cyclosporine concentrations, while cyp3a inducers may decrease cyclosporine concentrations. monitoring of concentrations and appropriate adjustment of gengraf dosage should be made as needed with concomitant use of either cyp3a inhibitors or inducers. cyclosporine may reduce the clearance of digoxin, colchicine, prednisolone, hmg-coa reductase inhibitors (statins), aliskiren, bosentan, dabigatran, repaglinide, nsaids, sirolimus, etoposide, and other drugs. severe digitalis toxicity has been seen within days of starting cyclosporine in several patients taking digoxin. literature and postmarketing cases of myotoxicity, including muscle pain and weakness, myositis, and rhabdomyolys

URL analysis for gengraf.com

http://www.gengraf.com/important-safety-information/
http://www.gengraf.com/resources/
http://www.gengraf.com/index.html

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: GENGRAF.COM
Registry Domain ID: 19097389_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.markmonitor.com
Registrar URL: http://www.markmonitor.com
Updated Date: 2018-01-03T10:15:26Z
Creation Date: 2000-02-04T19:34:09Z
Registry Expiry Date: 2019-02-04T19:34:09Z
Registrar: MarkMonitor Inc.
Registrar IANA ID: 292
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +1.2083895740
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: ABVEGDMZNS1.ABBVIE.COM
Name Server: ABVLUDMZNS1.ABBVIE.COM
Name Server: ABVSGDMZNS1.ABBVIE.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2018-03-18T15:47:10Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR MarkMonitor Inc.

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =gengraf.com

  PORT 43

  TYPE domain

DOMAIN

  NAME gengraf.com

  CHANGED 2018-01-03

  CREATED 2000-02-04

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

NSERVER

  ABVEGDMZNS1.ABBVIE.COM 159.180.132.57

  ABVLUDMZNS1.ABBVIE.COM 159.180.162.57

  ABVSGDMZNS1.ABBVIE.COM 159.180.178.57

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .